• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

银屑病关节炎患者疾病及治疗相关风险的减轻

Mitigation of disease- and treatment-related risks in patients with psoriatic arthritis.

作者信息

Bergman Martin, Lundholm Amy

机构信息

Taylor Hospital, 8 Morton Avenue, Suite 304, Ridley Park, PA, 19078, USA.

Lankenau Medical Center, Wynnewood, PA, USA.

出版信息

Arthritis Res Ther. 2017 Mar 20;19(1):63. doi: 10.1186/s13075-017-1265-5.

DOI:10.1186/s13075-017-1265-5
PMID:28320454
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5359960/
Abstract

Psoriatic arthritis is a part of the family of diseases referred to as spondyloarthropathies, a diverse group of chronic inflammatory disorders with common clinical, radiographic, and genetic features. Peripheral arthritis is the most common symptom of psoriatic arthritis and patients also frequently experience involvement of the entheses, spine, skin, and nails. Due to the diverse clinical spectrum of disease severity, tissues affected, and associated comorbidities, the treatment of psoriatic arthritis can be challenging and it is necessary to mitigate risks associated with both the disease and its treatment. These risks include disease-specific, treatment-related, and psychological risks. Disease-specific risks include those associated with disease progression that can limit functional status and be mitigated through early diagnosis and initiation of treatment. Risks also arise from comorbidities that are associated with psoriatic arthritis such as cardiovascular disease, obesity, diabetes mellitus, and gastrointestinal inflammation. Patient outcomes can be affected by the treatment strategy employed and the pharmacologic agents administered. Additionally, it is important for physicians to be aware of risks specific to each therapeutic option. The impact of psoriatic arthritis is not limited to the skin and joints and it is common for patients to experience quality-of-life impairment. Patients are also more likely to have depression, anxiety, and alcoholism. This article reviews the many risks associated with psoriatic arthritis and provides guidance on mitigating these risks.

摘要

银屑病关节炎是脊柱关节炎疾病家族的一部分,脊柱关节炎是一组具有共同临床、影像学和遗传特征的慢性炎症性疾病。外周关节炎是银屑病关节炎最常见的症状,患者还经常出现附着点、脊柱、皮肤和指甲受累。由于疾病严重程度、受累组织和相关合并症的临床谱各不相同,银屑病关节炎的治疗可能具有挑战性,因此有必要降低与疾病及其治疗相关的风险。这些风险包括疾病特异性风险、治疗相关风险和心理风险。疾病特异性风险包括与疾病进展相关的风险,这些风险可能会限制功能状态,可通过早期诊断和开始治疗来降低。风险也源于与银屑病关节炎相关的合并症,如心血管疾病、肥胖症、糖尿病和胃肠道炎症。患者的预后可能会受到所采用的治疗策略和所使用的药物的影响。此外,医生了解每种治疗选择的特定风险也很重要。银屑病关节炎的影响不仅限于皮肤和关节,患者出现生活质量受损很常见。患者也更有可能患有抑郁症、焦虑症和酗酒问题。本文综述了与银屑病关节炎相关的诸多风险,并提供了降低这些风险的指导。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df3c/5359960/5854082bf6d6/13075_2017_1265_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df3c/5359960/5854082bf6d6/13075_2017_1265_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df3c/5359960/5854082bf6d6/13075_2017_1265_Fig1_HTML.jpg

相似文献

1
Mitigation of disease- and treatment-related risks in patients with psoriatic arthritis.银屑病关节炎患者疾病及治疗相关风险的减轻
Arthritis Res Ther. 2017 Mar 20;19(1):63. doi: 10.1186/s13075-017-1265-5.
2
Psoriatic disease--from skin to bone.银屑病性疾病——从皮肤到骨骼
Nat Clin Pract Rheumatol. 2007 Dec;3(12):698-706. doi: 10.1038/ncprheum0670.
3
The Role of Tumor Necrosis Factor-α Blockers in Psoriatic Disease. Therapeutic Options in Psoriatic Arthritis.肿瘤坏死因子-α阻滞剂在银屑病性疾病中的作用。银屑病关节炎的治疗选择。
J Rheumatol Suppl. 2015 Nov;93:73-8. doi: 10.3899/jrheum.150642.
4
Comprehensive treatment of psoriatic arthritis: managing comorbidities and extraarticular manifestations.银屑病关节炎的综合治疗:合并症及关节外表现的管理
J Rheumatol. 2014 Nov;41(11):2315-22. doi: 10.3899/jrheum.140882.
5
Comorbidities in Psoriatic Arthritis.银屑病关节炎的合并症
Rheum Dis Clin North Am. 2015 Nov;41(4):677-98. doi: 10.1016/j.rdc.2015.07.008. Epub 2015 Sep 5.
6
Psoriatic arthritis: complexities, comorbidities and implications for the clinic.银屑病关节炎:复杂性、合并症及其临床意义
Expert Rev Clin Immunol. 2016;12(4):405-16. doi: 10.1586/1744666X.2016.1139453. Epub 2016 Jan 28.
7
Role of Agents other than Tumor Necrosis Factor Blockers in the Treatment of Psoriatic Arthritis.肿瘤坏死因子阻滞剂以外的药物在银屑病关节炎治疗中的作用
J Rheumatol Suppl. 2015 Nov;93:79-81. doi: 10.3899/jrheum.150643.
8
Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis.脊柱关节炎(包括银屑病关节炎)中抗肿瘤坏死因子治疗的最新进展。
Curr Opin Rheumatol. 2006 Jul;18(4):347-53. doi: 10.1097/01.bor.0000231901.19795.8a.
9
Infliximab in psoriasis and psoriatic arthritis.英夫利昔单抗治疗银屑病和银屑病关节炎。
BioDrugs. 2013 Jan;27 Suppl 1:13-23. doi: 10.1007/BF03325638.
10
Etanercept in the treatment of psoriatic arthritis.依那西普治疗银屑病关节炎
Actas Dermosifiliogr. 2015 May;106(4):252-9. doi: 10.1016/j.ad.2014.09.004. Epub 2014 Nov 20.

引用本文的文献

1
Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trial.在活动性银屑病关节炎患者中,无论基线特征如何,古塞库单抗对肿瘤坏死因子抑制剂反应不足的患者均有持续应答:3b期COSMOS临床试验结果
RMD Open. 2024 Dec 12;10(4):e004494. doi: 10.1136/rmdopen-2024-004494.
2
Upadacitinib to improve anxiety in patients with adalimumab-treated psoriatic arthritis: study protocol for a randomized controlled trial.度伐鲁单抗联合替西罗莫司治疗局部晚期或转移性实体瘤的安全性和有效性:一项多中心、开放标签的 II 期临床试验
Trials. 2024 Sep 5;25(1):590. doi: 10.1186/s13063-024-08429-7.
3

本文引用的文献

1
Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies.银屑病关节炎和银屑病患者的定制治疗方案:已确立及新型生物制剂和小分子疗法综述
Rheumatol Int. 2016 May;36(5):603-12. doi: 10.1007/s00296-016-3436-0. Epub 2016 Feb 18.
2
Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry.比较生物单药治疗与联合治疗对银屑病关节炎患者的疗效:来自 Corrona 登记处的结果。
RMD Open. 2015 Dec 30;1(1):e000181. doi: 10.1136/rmdopen-2015-000181. eCollection 2015.
3
Early intervention in psoriasis: Where do we go from here?
银屑病的早期干预:我们从这里走向何方?
Front Med (Lausanne). 2022 Dec 1;9:1027347. doi: 10.3389/fmed.2022.1027347. eCollection 2022.
4
Longitudinal analysis of the patient pathways to diagnosis of psoriatic arthritis.对银屑病关节炎诊断的患者路径进行纵向分析。
Arthritis Res Ther. 2021 Oct 1;23(1):252. doi: 10.1186/s13075-021-02628-2.
5
Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies.古塞单抗治疗附着点炎的疗效及其与疾病负担的关系:两项 3 期银屑病关节炎研究的 1 年结果。
Rheumatology (Oxford). 2021 Nov 3;60(11):5337-5350. doi: 10.1093/rheumatology/keab285.
6
Regeneration of Damaged Tendon-Bone Junctions (Entheses)-TAK1 as a Potential Node Factor.损伤的肌腱-骨连接(附着点)的再生-TAK1 作为一个潜在的节点因素。
Int J Mol Sci. 2020 Jul 22;21(15):5177. doi: 10.3390/ijms21155177.
7
Demography, baseline disease characteristics, and treatment history of psoriasis patients with self-reported psoriatic arthritis enrolled in the PSOLAR registry.纳入PSOLAR注册研究的自我报告患有银屑病关节炎的银屑病患者的人口统计学、基线疾病特征及治疗史。
BMC Rheumatol. 2018 Sep 29;2:29. doi: 10.1186/s41927-018-0034-7. eCollection 2018.
8
Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond.在 III 期随机对照试验中,托法替布对肿瘤坏死因子抑制剂应答不足的活动性银屑病关节炎患者的患者报告结局的影响:OPAL Beyond。
RMD Open. 2019 Jan 11;5(1):e000808. doi: 10.1136/rmdopen-2018-000808. eCollection 2019.
9
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs.托法替布或阿达木单抗与安慰剂比较:来自 OPAL Broaden 研究的患者报告结局,该研究为 III 期研究,纳入对常规合成疾病修饰抗风湿药物应答不足的活动性银屑病关节炎患者。
RMD Open. 2019 Jan 11;5(1):e000806. doi: 10.1136/rmdopen-2018-000806. eCollection 2019.
10
Treatment patterns, unmet need, and impact on patient-reported outcomes of psoriatic arthritis in the United States and Europe.美国和欧洲银屑病关节炎的治疗模式、未满足的需求及其对患者报告结局的影响。
Rheumatol Int. 2019 Jan;39(1):121-130. doi: 10.1007/s00296-018-4195-x. Epub 2018 Nov 13.
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis.
银屑病关节炎研究与评估小组 2015 年银屑病关节炎治疗建议。
Arthritis Rheumatol. 2016 May;68(5):1060-71. doi: 10.1002/art.39573. Epub 2016 Mar 23.
4
Psoriatic arthritis: complexities, comorbidities and implications for the clinic.银屑病关节炎:复杂性、合并症及其临床意义
Expert Rev Clin Immunol. 2016;12(4):405-16. doi: 10.1586/1744666X.2016.1139453. Epub 2016 Jan 28.
5
Analysis of HLA-B15 and HLA-B27 in spondyloarthritis with peripheral and axial clinical patterns.具有外周和中轴临床模式的脊柱关节炎中HLA - B15和HLA - B27的分析
BMJ Open. 2015 Nov 11;5(11):e009092. doi: 10.1136/bmjopen-2015-009092.
6
What makes psoriatic and rheumatoid arthritis so different?导致银屑病关节炎和类风湿关节炎如此不同的原因是什么?
RMD Open. 2015 Apr 28;1(1):e000025. doi: 10.1136/rmdopen-2014-000025. eCollection 2015.
7
Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial.早期银屑病关节炎炎症严格控制的效果(TICOPA):一项英国多中心、开放标签、随机对照试验。
Lancet. 2015 Dec 19;386(10012):2489-98. doi: 10.1016/S0140-6736(15)00347-5. Epub 2015 Oct 1.
8
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.司库奇尤单抗抑制银屑病关节炎患者的白细胞介素-17A。
N Engl J Med. 2015 Oct;373(14):1329-39. doi: 10.1056/NEJMoa1412679.
9
Promoting patient-centred care in psoriatic arthritis: a multidisciplinary European perspective on improving the patient experience.在银屑病关节炎中促进以患者为中心的护理:欧洲多学科视角下对改善患者体验的探讨
J Eur Acad Dermatol Venereol. 2016 Apr;30(4):576-85. doi: 10.1111/jdv.13306. Epub 2015 Sep 16.
10
Psoriatic arthritis: latest treatments and their place in therapy.银屑病关节炎:最新治疗方法及其在治疗中的地位。
Ther Adv Chronic Dis. 2015 Jul;6(4):194-203. doi: 10.1177/2040622315582354.